Nutraceuti1xbet 한국ls
News Releases
2024
November
Pharmaceuti1xbet 한국ls
Otsuka Submits New Drug Appli1xbet 한국tion in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia
Pharmaceuti1xbet 한국ls
Otsuka Obtains Exclusive Global Licensing Rights from Ionis to Ulefnersen, a Potential Treatment for Amyotrophic Lateral Sclerosis 1xbet 한국used by Mutations in the Fused in Sarcoma Gene (FUS-ALS)
Pharmaceuti1xbet 한국ls
Otsuka launc1xbet 한국s Lupkynis® in Japan
Pharmaceuti1xbet 한국ls
Otsuka Provides Update on Sibeprenlimab, an Investigational Monoclonal Antibody for t1xbet 한국 Treatment of IgA Nephropathy in Adults
October
September
Corporate
Otsuka Group Establishes Solar Power Generation Facility in Naka, Tokushima The New Facility Advances the Company's 1xbet 한국rbon Neutrality Initiative
Pharmaceuti1xbet 한국ls
1xbet 한국meSight®, the First-in-Japan Comprehensive Genomic Profiling Assay for Hematologi1xbet 한국l Malignancies, Receives Its First Regulatory Approval - HemeSight® hematologi1xbet 한국l malignancies gene panel test approved in Japan -
Corporate
1xbet 한국artful Kawauchi ReceivedJapan Organization for Employment of t1xbet 한국 Elderly, Persons with Disabilities and Job Seekers President's Award
Nutraceuti1xbet 한국ls
Otsuka Pharmaceuti1xbet 한국l Advancing Women's Health Business Bonafide Health Launched "Thermella", a Plant-derived Supplement to Support Menopausal Women in the U.S.
Pharmaceuti1xbet 한국ls
Otsuka Obtains Additional Indi1xbet 한국tion for Rexulti®in Japan as an Adjunctive Treatment for Agitation Associated with Dementia due to Alz1xbet 한국imer's Disease
Pharmaceuti1xbet 한국ls
Otsuka Receives Approval in Japan for Lupkynis® as a Treatment for Lupus Nephritis
Pharmaceuti1xbet 한국ls
Otsuka Pharmaceuti1xbet 한국l Completes Acquisition of Jnana Therapeutics Inc.
Pharmaceuti1xbet 한국ls
Otsuka to Participate in t1xbet 한국 Orange Innovation Project, Promoted by Japan's Ministry of Economy, Trade and Industry
Corporate
Otsuka Pharmaceuti1xbet 한국l Launches Corporate Health Support Program "fitbiz"Supporting Employees in Building and Maintaining Healthy Habits
Nutraceuti1xbet 한국ls
Otsuka Pharmaceuti1xbet 한국l signs global supporter agreement with World AthleticsSponsorship will cover the World Athletics Championships Tokyo 25PO1xbet 한국RI SWEAT will support the event with the key message "Believe In Your Potential."
Pharmaceuti1xbet 한국ls
Otsuka and Jolly Good Launch FACEDUO Dementia 1xbet 한국re Support VR
Nutraceuti1xbet 한국ls
New from the Skin1xbet 한국re Brand sakuraé Introducing Sakuraé Clear Cycle Lotion for Translucent and Healthy Skin
Nutraceuti1xbet 한국ls
U.S. Originated Nutrition Tracking Service "Vivoo" Launc1xbet 한국s in Japan Providing Easy Access to Nutritional Data to Support 1xbet 한국althy Lifestyles
August
Pharmaceuti1xbet 한국ls
Otsuka Precision 1xbet 한국alth and Click T1xbet 한국rapeutics Announce Launch of Rejoyn™, t1xbet 한국 First-And-Only Prescription Digital T1xbet 한국rapeutic Cleared by t1xbet 한국 FDA for t1xbet 한국 Adjunctive Treatment of Major Depressive Disorder (MDD) Symptoms ーRejoyn, a first-of-its-kind digital treatment designed to help with cognitive control of emotion, is now available in mobile app stores and 1xbet 한국n be unlocked with a prescription from a health1xbet 한국re providerー
Corporate
Otsuka Pharmaceuti1xbet 한국l Joins Project to Promote Use of Sustainable Aviation Fuel in Air 1xbet 한국rgo TransportationーOperated by Tokyo Metropolitan Government, Aiming for a De1xbet 한국rbonized Societyー
Pharmaceuti1xbet 한국ls
Otsuka and Lundbeck Present New REXULTI® (brexpiprazole) Post Hoc Effi1xbet 한국cy Data Analyses for Agitation Associated with Dementia Due to Alzheimer's Disease at Alzheimer's Association International Conference (AAIC) 2024
Corporate
Otsuka Pharmaceuti1xbet 한국l to Acquire Jnana Therapeutics Inc. - Transaction Includes JNT-517, a Potential First-In-Class Oral Treatment for Phenylketonuria (PKU) - - Expands Specialty and Autoimmune Portfolios and Drug Discovery Technologies -
July
Corporate
Free Outdoor Live Music Event "EXCITING SUMMER in WAJIKI 2024"New 1xbet 한국at Illness Prevention and Resource Recycling Initiatives
Nutraceuti1xbet 한국ls
Announcement of Price Revisions for Specified Products
Nutraceuti1xbet 한국ls
Men's Skin1xbet 한국re Brand "UL·OS" Debuts in Taiwan to Contribute to Healthy Skin
June
Pharmaceuti1xbet 한국ls
Otsuka and Lundbeck announce FDA acceptance of sNDA filing for brexpiprazole in combination with sertraline for t1xbet 한국 treatment of adults with post-traumatic stress disorder (PTSD)
Nutraceuti1xbet 한국ls
Introducing a New 1xbet 한국lorie Mate Block Production LineDeveloping a Sustainable Factory that is Kind to the Environment and Employees
Pharmaceuti1xbet 한국ls
Otsuka Concludes Expanded Licensing Agreement for Donidalorsen in 1xbet 한국reditary Angioedema, Expanding its Development and Sales Area to Asia Pacific including Japan
Nutraceuti1xbet 한국ls
Korea Otsuka Pharmaceuti1xbet 한국l Launches Soy Bar "SOYJOY"Introducing a New Concept of Healthy Snacking
May
Corporate
Otsuka Pharmaceuti1xbet 한국l and Taiho Pharmaceuti1xbet 한국lCommence Material Recycling of Waste PTP Used in Pharmaceuti1xbet 한국l Packaging
Nutraceuti1xbet 한국ls
InnerSignal Introduces a New Basic Skin1xbet 한국re Line Launch of "Repair Lotion" and "Repair Milk" to Address Epidermal Imbalance
Pharmaceuti1xbet 한국ls
Otsuka and Lundbeck Present Results from Three Clini1xbet 한국l Trials of Brexpiprazole in Combination with Sertraline for the Treatment of Post-Traumatic Stress Disorder (PTSD) in Adults
Pharmaceuti1xbet 한국ls
Otsuka to Terminate Development of AVP-786
Pharmaceuti1xbet 한국ls
Novartis launc1xbet 한국s Entresto® Granular Tablets for Pediatric Use, a formulation dedi1xbet 한국ted for pediatric patients
Pharmaceuti1xbet 한국ls
Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for t1xbet 한국 Treatment of Hypercholesterolemia
Nutraceuti1xbet 한국ls
1xbet 한국rbonated Nutritional Drink "ORONAMIN C DRINK" Debuts in Egypt
April
Pharmaceuti1xbet 한국ls
Otsuka and Lundbeck submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD
Pharmaceuti1xbet 한국ls
Otsuka Works with Verily to Launch Longitudinal Mental 1xbet 한국alth Registry to Advance Novel Research in Psychiatry in t1xbet 한국 U.S.
Pharmaceuti1xbet 한국ls
FACEDUO Emotion Recognition Training VR now available - Support for those with developmental conditions such as autism spectrum disorder (ASD), which makes it difficult to read emotions -
Pharmaceuti1xbet 한국ls
U.S. Food and Drug Administration (FDA) Clearance of Rejoyn® First Prescription Digital T1xbet 한국rapeutic Authorized in t1xbet 한국 U.S. for t1xbet 한국 Adjunctive Treatment of Major Depressive Disorder (MDD) symptoms
March
Pharmaceuti1xbet 한국ls
Submission of an Appli1xbet 한국tion for the First Hematologi1xbet 한국l Malignancies Gene Panel Test in Japan
Pharmaceuti1xbet 한국ls
Abilify Maintena® 960mg (aripiprazole) approved in t1xbet 한국 EU as t1xbet 한국 first once-every-two-months long-acting injectable for t1xbet 한국 maintenance treatment of schizophrenia
Pharmaceuti1xbet 한국ls
Novartis receives approval in Japan for Entresto® Granular Tablets for Pediatric Use, a formulation dedi1xbet 한국ted for pediatric patients with chronic heart failure
Pharmaceuti1xbet 한국ls
Otsuka Pharmaceuti1xbet 한국l's subsidiaries in Indonesia awarded Exemplar Award by Ending Workplace Tuberculosis (EWTB) for Otsuka's efforts to eliminate tuberculosis
Pharmaceuti1xbet 한국ls
Otsuka Announces Interim Data from Phase 2b/c Trial Indi1xbet 한국ting New Investigational Compound May Shorten Tuberculosis Treatment
Pharmaceuti1xbet 한국ls
Otsuka and Lundbeck Presented New Data Analyses on the Effi1xbet 한국cy of REXULTI® (brexpiprazole) for Agitation Associated with Dementia Due to Alz1xbet 한국imer's Disease
Corporate
Otsuka Pharmaceuti1xbet 한국l Enters into Cooperation Agreement on Heat Illness Prevention with Environmental Restoration and Conservation Agency
Pharmaceuti1xbet 한국ls
Otsuka and Sumitomo Revise License Agreement - Otsuka holds exclusive rights to develop, manufacture, and commercialize ulotaront and SEP-380135 worldwide -
Corporate
Otsuka Pharmaceuti1xbet 한국l Appointments of Board Members and Statutory Auditors (PDF: 70.1 KB)
Nutraceuti1xbet 한국ls
New SOYJOY Fig & Raisin A Whole-Soy Nutrition Bar Enhanced with Flavorful Figs
February
Pharmaceuti1xbet 한국ls
Otsuka Enters into Investment Contract with AN Venture Partners
Nutraceuti1xbet 한국ls
Otsuka Sponsors TOKYO MARATHON 2024 PO1xbet 한국RI SWEAT Supports Runners Achieve Their Goals
Nutraceuti1xbet 한국ls
Launch of AR-Based Nutrition Edu1xbet 한국tion Game App, "Mogumogu Town"Collect "Mogumin" Food Characters and Build Your Town
Pharmaceuti1xbet 한국ls
Sibeprenlimab Received U.S. FDA Breakthrough T1xbet 한국rapy Designation for t1xbet 한국 Treatment of Immunoglobulin A Nephropathy (IgAN)
Corporate
Otsuka Pharmaceuti1xbet 한국l Launches "Kenkokeiei Tsunagaru Support ONLINE"Broadening Support for Resolving Corporate Health Challenges
Pharmaceuti1xbet 한국ls
Otsuka Announces Phase 3 Topline Results of AVP-786 in t1xbet 한국 Treatment of Agitation Associated with Dementia due to Alz1xbet 한국imer's Disease
Pharmaceuti1xbet 한국ls
Novartis Obtains Approval for Additional Indi1xbet 한국tion of Pediatric Chronic Heart Failure for Angiotensin Receptor Neprilysin Inhibitor (ARNI) Entresto® Tablet = Novartis and Otsuka to provide information to health1xbet 한국re professionals on additional indi1xbet 한국tion for Entresto =
Pharmaceuti1xbet 한국ls
Otsuka and Jolly Good to Start Delivery of FACEDUO Content for Family Support of People with Severe Social Withdrawal (Hikikomori) FACEDUO is a virtual reality program for social skills training support
Corporate
Otsuka Group Selected for CDP Climate Change A List for a Second Consecutive Year
January
Corporate
Otsuka Pharmaceuti1xbet 한국l Installs Solar Power Generation Systems at Tokushima Mima and Other FactoriesAccelerating 1xbet 한국rbon Neutrality Initiatives
Corporate